ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,534,463, issued on Jan. 27, was assigned to Incyte Corp. (Wilmington, Del.) and Incyte Holdings Corp. (Wilmington, Del.).
"Substituted tricyclic compounds as FGFR inhibitors" was invented by Liangxing Wu (Wilmington, Del.), Colin Zhang (Berwyn, Pa.), Chunhong He (Boothwyn, Pa.), Liang Lu (Hockessin, Del.) and Wenqing Yao (Chadds Ford, Pa.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer."
The patent was filed on Oct. 20, 2023, under App...